Post hoc analyses of the DAPA-CKD trial revealed that a slower decline in eGFR was noted regardless of the presence or absence of an initial eGFR decline [26], suggesting that the renoprotective effects of SGLT2 inhibitors can be expected even in cases wherein an initial decline in eGFR does not occur. Here, SLC5A2 is linked to chronic kidney disease.